Metraipolis › archive › dc_301d160f56aa
Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines — Europe PMC PMID:41338056
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41338056
- DOI
- 10.1016/j.breast.2025.104664
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T06:07:34.340Z
- SHA-256 of the archived text
ca7fcd6a96aa2e239b326676d0976a98479781b2c91ae59a85865b73ff59fa75- Stable URL of this page
https://metraipolis.com/documento/dc_301d160f56aa
How to cite
Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines — Europe PMC PMID:41338056 — Europe PMC (en), https://europepmc.org/article/MED/41338056 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_301d160f56aa (Metraipolis archive dc_301d160f56aa, sha256 ca7fcd6a96aa2e239b326676d0976a98479781b2c91ae59a85865b73ff59fa75)
BibTeX
@misc{dc301d160f56aa,
title = {Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines — Europe PMC PMID:41338056},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41338056},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_301d160f56aa; sha256 ca7fcd6a96aa2e239b326676d0976a98479781b2c91ae59a85865b73ff59fa75},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41338056. Agents can read the archived copy with the MCP tool read_document.